Project Grant R61HL183037
- Federal Project Grant Award Summary The University of Pittsburgh received a $593,985 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2029. The project develops artificial intelligence (AI) techniques and systems that convert photoplethysmography (PPG) measurements from off-the-shelf wearable devices into multi-lead electrocardiogram (ECG)...
- Federal Project Grant Award Summary The University of Pittsburgh received a $238,500 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2026, through April 30, 2028. The project, titled "Words to Live By: Leveraging Natural Language Processing and Machine Learning to Enhance Prehospital Triage Algorithms," will develop and validate algorithmic tools that utilize Natural Language...
- Federal Project Grant Award Summary The University of Pittsburgh received a $190,188 Project Grant award dated April 10, 2026, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a five-year research initiative through March 31, 2031, investigating biomarkers and predictors of treatment response in chronic anemia associated with sickle cell disease (SCD). The research will evaluate how...
- Federal Project Grant Summary The University of Pittsburgh received a $1,420,780 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion targeted for May 31, 2029. The grant funds basic and translational research to elucidate the mechanistic requirements of ALK1 (Activin Receptor-Like Kinase 1) ligands—specifically bone morphogenetic proteins 9 and 10 (BMP9 and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a Project Grant totaling $190,168 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 2, 2026, with completion targeted for April 30, 2031. This award supports Dr. Malamo Countouris' research program investigating strategies to reverse left ventricular remodeling in women with a history of preeclampsia who subsequently develop hypertension. The research...
- Federal Grant Award Summary The University of Pittsburgh received a $109,076 Project Grant award from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 10, 2025, with completion targeted for September 9, 2029. Based on the award documentation and program parameters, this funding supports hypothesis-driven research in cardiovascular science, consistent with NHLBI's mission to advance prevention and...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $222,750 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 21, 2025, with a completion date of June 30, 2027. The grant supports the development of a clinical decision support questionnaire designed to identify barriers to blood pressure control among adults with hypertension. This tool addresses a critical gap in...
- Federal Grant Award Summary The University of Pittsburgh received $782,341 in funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant awarded July 15, 2026, with completion targeted for May 31, 2031. The project will develop and validate an adaptive, artificial intelligence-guided, closed-loop neuromodulation system designed to predict and prevent ventricular arrhythmias (VAs)—including ventricular...
- Federal Project Grant Summary The University of Pittsburgh received $767,953 in funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project titled "Structural Biomimicry to Improve Engineered Heart Valve Leaflet Function and Remodeling." The award was obligated on July 1, 2026, with an ultimate completion date of March 31, 2030. This project addresses critical gaps in tissue-engineered heart valve...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Northwestern University a Project Grant of $793,184 on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the AUTO2 Trial, a 2×2 factorial, patient-randomized controlled trial examining digitally-enabled home blood pressure monitoring strategies for patients with uncontrolled hypertension. The research will evaluate the comparative effectiveness of automated...
The University of Pittsburgh received a $1,019,556 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 13, 2026, for development and implementation of "The Hypertension Toolkit: An Adaptive Mobile Health Blood Pressure Intervention." The primary deliverable is a theory-informed chronic disease self-management intervention targeting blood pressure control in resource-limited primary care settings. Core products include: (1) a validated Hypertension Virtual Coach mobile application that delivers personalized education, non-pharmacologic guidance, and self-efficacy support; (2) home blood pressure monitoring (HBPM) protocols and supporting workbooks for clinical trial participants; and (3) augmented intervention tactics—a text-based digital health program for modest augmentation and a text-plus-pharmacist co-management option for vigorous augmentation—designed to address treatment non-response among trial participants. The award funds execution of a randomized clinical trial (N=378) employing a Sequential Multiple Assignment Randomized Trial (SMART) design across community-based and federally qualified health centers through June 30, 2027. Deliverables include study coordination with partner clinics, Community Engagement Collaborative guidance on toolkit design, virtual agent refinement, trial launch, and primary outcome assessment of the virtual agent's six-month effect on systolic blood pressure control. Secondary deliverables measure the comparative effectiveness of modest versus vigorous augmentation tactics for non-responders re-randomized at 2- or 4-month intervals.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 7/10/26 |